Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure

Table 1 Characteristics of patients with hepatitis B virus-associated acute-on-chronic liver failure at the time of admission

Parameters	G-CSF group	Control group	P value
Gender (male %)	22 (81.5)	22 (78.6)	0.755
Age (yr)	43.5 (29-63)	45.9 (22-65)	0.332
WBC (109/L)	5.79 ± 1.81	6.61 ± 1.71	0.443
Neutrophil (109/L)	3.53 ± 1.46	3.82 ± 1.17	0.114
Platelets (109/L)	182 (147-215)	174 (149-175)	0.680
ALT (U/L)	276 (197-801)	252 (189-1239)	0.430
AST (U/L)	246 (195-788)	251 (187-980)	0.544
Total bilirubin (μmol/L)	336 (181-519)	320.0 (174.5-519.8)	0.605
Cr (μmol/L)	83.8 ± 16.9	85.4 ± 53.87	0.475
INR	2.11 ± 0.28	2.34 ± 0.34	0.606
ALB (g/L)	29.11 ± 4.05	28.75 ± 4.63	0.596
HBV DNA (log10)	5.11 ± 1.37	5.55 ± 1.59	0.280
CTP score	12.17 ± 1.47	12.25 ± 1.29	0.349
MELD score	25.11 ± 3.30	26.30 ± 4.12	0.588

Values are shown as mean ± SD. WBC: White blood cell; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; Cr: Creatine; INR: International normalized ratio; ALB: Albumin; CTP: Child-Turcotte-Pugh; MELD: Model for end stage of liver disease; HBV: Hepatitis B virus; G-CSF: Granulocyte-colony stimulating factor.